<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02495285</url>
  </required_header>
  <id_info>
    <org_study_id>HC-O-H-1406</org_study_id>
    <nct_id>NCT02495285</nct_id>
  </id_info>
  <brief_title>Gelatines in Pediatric PatientS</brief_title>
  <acronym>GPS</acronym>
  <official_title>Infusion of Gelatine Solutions in Pediatric Patients Aged up to 12 Years</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>B. Braun Melsungen AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>B. Braun Melsungen AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of volume replacement is to compensate a reduction in the intravascular volume e.g.
      during surgery and to counteract hypovolemia in order to maintain hemodynamics and vital
      functions. So far, there is only few data on the safety and efficacy of the products under
      investigation in children.

      The primary aim of this non-interventional observational study (NIS) is to collect further
      data of gelatine solutions in a large pediatric population during routine clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">May 2020</completion_date>
  <primary_completion_date type="Actual">May 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Dosing of the products during surgery</measure>
    <time_frame>Observation period will start 2 hours prior first infusion of gelatine solutions and will end 2 hours after the last gelatine infusion stopped.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Potentia hydrogenii</measure>
    <time_frame>Observation period will start 2 hours prior first infusion of gelatine solutions and will end 2 hours after the last gelatine infusion stopped.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin</measure>
    <time_frame>Observation period will start 2 hours prior first infusion of gelatine solutions and will end 2 hours after the last gelatine infusion stopped.</time_frame>
    <description>g/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lactate</measure>
    <time_frame>Observation period will start 2 hours prior first infusion of gelatine solutions and will end 2 hours after the last gelatine infusion stopped.</time_frame>
    <description>mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematocrit</measure>
    <time_frame>Observation period will start 2 hours prior first infusion of gelatine solutions and will end 2 hours after the last gelatine infusion stopped.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>Observation period will start 2 hours prior first infusion of gelatine solutions and will end 2 hours after the last gelatine infusion stopped.</time_frame>
    <description>mmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum prolin</measure>
    <time_frame>Observation period will start 2 hours prior first infusion of gelatine solutions and will end 2 hours after the last gelatine infusion stopped.</time_frame>
    <description>µmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>Observation period will start 2 hours prior first infusion of gelatine solutions and will end 2 hours after the last gelatine infusion stopped.</time_frame>
    <description>mg/dl</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of (Serious) adverse events / reactions</measure>
    <time_frame>Observation period will start 2 hours prior first infusion of gelatine solutions and will end 2 hours after the last gelatine infusion stopped.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart rate</measure>
    <time_frame>Observation period will start 2 hours prior first infusion of gelatine solutions and will end 2 hours after the last gelatine infusion stopped.</time_frame>
    <description>beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean arterial pressure</measure>
    <time_frame>Observation period will start 2 hours prior first infusion of gelatine solutions and will end 2 hours after the last gelatine infusion stopped.</time_frame>
    <description>mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-up assessed by number of participants with post-operative complications</measure>
    <time_frame>At discharge from the hospital or in-hospital 3 months after start of gelatine infusion, whatever occurs first.</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">600</enrollment>
  <condition>Treatment of Hypovolemia and Shock</condition>
  <arm_group>
    <arm_group_label>Gelofusine 4%</arm_group_label>
    <description>Children age ≤ 12 years</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gelaspan 4%</arm_group_label>
    <description>Children age ≤ 12 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gelofusine 4%</intervention_name>
    <arm_group_label>Gelofusine 4%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gelaspan 4%</intervention_name>
    <arm_group_label>Gelaspan 4%</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        children
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion:

          -  Age ≤ 12 years

          -  American Society of Anesthesiologists (ASA) risk score: ≤ III

          -  Peri-operative infusion of gelatine solutions

          -  Informed consent and/or data protection declaration signed by parents/legal guardians
             (according to local requirements)

        Exclusion:

          -  Inclusion in another investigational study in the field of volume replacement which
             could interfere with the routine clinical practice regarding the administration of the
             gelatine solutions

          -  In addition contraindications as outlined in the valid local Summaries of Product
             Characteristics (SmPCs) have to be considered.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Sümpelmann, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinische Hochschule Hannover (MHH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cardiology Hospital</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auf der Bult</name>
      <address>
        <city>Hannover</city>
        <zip>30173</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover, Pädiatrische Kardiologie und Intensivmedizin</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Hallerwiese/Cnopf´sche Kinderklinik</name>
      <address>
        <city>Nuernberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart, Olgahospital und Frauenklinik</name>
      <address>
        <city>Stuttgart</city>
        <zip>70174</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Policlinico Universitaria G. Rodolico -Vittorio Emanuele</name>
      <address>
        <city>Catania</city>
        <zip>I-95100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale dei Bambini Vittore Buzzi</name>
      <address>
        <city>Milano</city>
        <zip>I-20154</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sant Joan de Déu</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vall d'Hebron University Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma De Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's NHS FT</name>
      <address>
        <city>Liverpool</city>
        <zip>L12 2AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 12, 2015</study_first_submitted>
  <study_first_submitted_qc>July 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2015</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pediatric patients gelatine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypovolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polygeline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

